Page data last changed: . Chemistry registry snapshot: . Registry refreshes and identity assessments are separate from scientific content review.
A ghrelin analog studied for gut motility rather than growth hormone effects.
Also known as: RM-131 · BIM-28131 · ghrelin receptor agonist
Part of the Growth hormone & IGF peptides cluster
Overview
Relamorelin is a synthetic, centrally penetrant agonist of the ghrelin/growth hormone secretagogue receptor developed as a prokinetic. It has been investigated in clinical trials for diabetic gastroparesis and chronic constipation and is not an approved medicine authorized by Health Canada. This page is educational and is not medical advice.
Source & context
Biological / chemical source: Synthetic peptide analog of ghrelin
Primary research or clinical context: Investigational for diabetic gastroparesis and related motility disorders; not an approved medicine and not authorized by Health Canada
Motility angle
Ghrelin accelerates gastric emptying, and relamorelin was designed to harness that prokinetic effect. This positions it differently from GH-focused secretagogues, even though it acts at the same receptor family.
Development status
Relamorelin has been studied in phase II trials for gastroparesis and related conditions, but its development path has been uncertain and it remains investigational. Availability and approval status may change over time and differ by country.
Structure & chemistry
Molecular identity & reference confidence
Source-supported reference
Reference values are taken from the cited molecular record or curated profile. A database match is not independent laboratory verification; modifications, counter-ions, and formulations can change the measured mass.
- Molecular form
- Relamorelin (source record; form not independently established)
- Species
- Not established by this molecular identity audit
- Termini (N / C)
- Not specified / Not specified
Average reference mass
Reference policy updated: 2026-10-05
- PubChem molecular record · 2026-10-01
- Molecular formula
- C43H50N8O5S
- Average reference mass
- ≈ 791
- PubChem CID: 44251769
- CAS RN: 661472-41-9
- UNII: BIW199E18V
Chemistry values: PubChem · fetched 2026-10-01.
Clinical development snapshot
ClinicalTrials.gov lists 13 registered studies with “Relamorelin” as an intervention (snapshot 2026-09-06). A registry footprint is not evidence of efficacy or approval.
| NCT | Title | Phase | Status | Updated |
|---|---|---|---|---|
| NCT03420781 | A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis Study 03 | Phase 3 | terminated | 2021-12-22 |
| NCT03786380 | Diabetic Gastroparesis Study 05 | Phase 3 | terminated | 2021-12-15 |
| NCT03383146 | A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis Study 04 | Phase 3 | terminated | 2021-11-23 |
| NCT03426345 | Study to Evaluate the Safety and Efficacy of Relamorelin in Participants With Diabetic Gastroparesis Study 02 | Phase 3 | terminated | 2021-08-06 |
| NCT03285308 | A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis 01 | Phase 3 | terminated | 2021-07-29 |
| NCT02357420 | Safety and Efficacy of Relamorelin Administered to Participants With Vomiting Symptoms and Moderate to Severe | Phase 2 | completed | 2019-07-24 |
Relamorelin — reconstitution calculator
Enter how much peptide is in the vial and how much diluent (e.g. bacteriostatic water) is added. The tool returns the resulting solution concentration — and, for any amount you type, the volume it corresponds to. This is educational arithmetic, not a dosing recommendation.
Reference form: Relamorelin (source record; form not independently established)Average reference mass: 791 Da
Enter an amount to see the volume it corresponds to.
Educational concentration mathematics only. This tool does not recommend a dose, amount, or protocol, and nothing here is medical advice. Many peptides are not authorized by Health Canada for human use — see our reconstitution and bacteriostatic-water guides for context.
FAQ about Relamorelin
What is Relamorelin?+
Relamorelin is a synthetic, centrally penetrant agonist of the ghrelin/growth hormone secretagogue receptor developed as a prokinetic. It has been investigated in clinical trials for diabetic gastroparesis and chronic constipation and is not an approved medicine authorized by Health Canada. This page is educational and is not medical advice.
What Canadian product status is recorded for Relamorelin?+
Canadian product status for Relamorelin has not been verified in this profile. No verified record here does not mean no authorization exists. Status depends on the product, formulation and use; consult Health Canada's product records.
What is the typical length of Relamorelin?+
Relamorelin is not a classic amino-acid chain peptide in the same sense; see the profile for classification details.
Related peptides
References & further reading
- 1.Bassotti (2016). Relamorelin to Treat Constipation: "Pusher" or Pushover?. Dig Dis Sci
- 2.Camilleri et al. (2015). Emerging treatments in Neurogastroenterology: relamorelin: a novel gastrocolokinetic synthetic ghrelin agonist. Neurogastroenterol Motil
- 3.Chedid et al. (2017). Relamorelin for the treatment of gastrointestinal motility disorders. Expert Opin Investig Drugs
- 4.Patel et al. (2023). Relamorelin in Gastroparesis and Diabetic Gastroparesis: A Meta-Analysis on Its Efficacy and Safety. Cureus
- 5.Nelson et al. (2016). Effects of ghrelin receptor agonist, relamorelin, on gastric motor functions and satiation in healthy volunteers. Neurogastroenterol Motil
- 6.Acosta et al. (2015). Relamorelin Relieves Constipation and Accelerates Colonic Transit in a Phase 2, Placebo-Controlled, Randomized Trial. Clin Gastroenterol Hepatol
- 7.Acosta et al. (2016). Short-Term Effects of Relamorelin on Descending Colon Motility in Chronic Constipation: A Randomized, Controlled Trial. Dig Dis Sci
- 8.Lembo et al. (2016). Relamorelin Reduces Vomiting Frequency and Severity and Accelerates Gastric Emptying in Adults With Diabetic Gastroparesis. Gastroenterology
- 9.PubChem — compound summary for Relamorelin (CID 85364156)
- 10.Wikipedia — Relamorelin